Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
about
Patient expectations did not predict outcome of drug and behavioral treatment of urgency urinary incontinenceFactors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study.Electronic bladder diaries of differing duration versus a paper diary for data collection in overactive bladder.Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective studyNeurogenic detrusor overactivity is associated with decreased expression and function of the large conductance voltage- and Ca(2+)-activated K(+) channelsTreating overactive bladder in the elderly.Effect of pharmacological treatment for urinary incontinence in the elderly and frail elderly: A systematic review.The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection.Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.Overactive bladder syndrome in older people.Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin.Solifenacin at 3 years: a review of efficacy and safety.Role of fesoterodine in the treatment of overactive bladder.Social, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms.Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction.Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.Antimuscarinic treatment in overactive bladder: special considerations in elderly patients.Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.Emerging drugs for autonomic dysfunction in Parkinson's disease.Overactive bladder in elderly men: epidemiology, evaluation, clinical effects, and management.Management of OAB in those over age 65.Solifenacin: pharmacology and clinical efficacy.Systematic literature review of clinical trials evaluating pharmacotherapy for overactive bladder in elderly patients: An assessment of trial quality.Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms.Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?Patient-reported Goal and Goal Achievement: The Most Individualized Method of Outcome Assessment in Patients with Lower Urinary Tract Symptoms.Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non-neurogenic overactive bladder.Clinical Guideline for Female Lower Urinary Tract Symptoms.Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome.Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg.Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.Clinical guidelines for overactive bladder.
P2860
Q30425150-AA6C8618-FBA1-4574-B751-AE0F82EB9114Q30794849-0275DB76-0DDD-4026-8761-E6F9E1988C65Q30980428-DCFE8782-BFB3-492E-A76B-345C7EED330DQ31013378-C445448E-56B6-41E7-82D4-37C122E7352FQ34352604-CA3EDFB2-2610-4B9B-AC8E-A32E48F9981DQ34826716-ED5E528B-8C90-4385-9BA7-2942DDC01A17Q35347702-C11BD67C-28C8-40CA-A69E-610BF309225DQ35556196-C129F347-DED8-421F-86F1-95D52068FC02Q36038099-711AF203-E145-4F13-A629-6B2D11E492A8Q36655193-AC1F33B2-04C5-4163-9911-FFD43FB51138Q36779724-DD71FE39-61A7-4ACE-B837-C1B3276A9BECQ37192944-06A12443-DF12-4B85-AF04-30FC4F81F1DDQ37226401-7A60776A-78AF-49F1-8974-39E03C95CF4FQ37283542-0D1C6844-EA91-4BF0-8B67-10A86DC341C8Q37373376-9AA4D6EC-6DD1-4AE5-8993-24F93ADA2F1AQ37399563-DF302D00-D82A-4AFE-8685-25EB989044F3Q37484824-165B911C-A75E-4FBC-ACF6-DC17349530C8Q37763286-144D7118-DA2F-4E32-B2ED-3A6DE3CC1227Q37864717-1ACB7D6A-2730-463A-AD36-3A96B534C69DQ37879017-B4F08DF6-402F-4F8D-8C5A-E86B05390E1BQ37914849-F5DCCA46-21C2-4637-81BA-7163E973062AQ38020185-40C56230-7B2D-4CFC-8D6D-8CCAB541A5F1Q38032608-5A4A236E-BBC5-4FA2-8EB5-C88FD0940BCDQ38078434-C40BC8C5-0E02-4168-ADC0-C75D404E5D36Q38126429-CE38324D-150F-4DCB-A7F5-6774049BC537Q38127155-C44D92CB-9926-4F58-947C-1D8F28201850Q38177369-CE8D3D4B-A581-4460-9624-ABB78C3DF851Q38648674-B8690BAB-D6F4-4A27-9673-7D2E8920E26EQ39020998-8DAA7E41-3912-49E2-9A3B-17B8FEA39547Q39246328-536FF6B8-3DA7-459B-9193-A62611459AD9Q39342723-5C4B3DBA-2E27-4552-A371-5F78EEA40EB3Q39412362-D61EE1E9-FBF2-4C79-9486-4D8EBAD1C701Q40202594-DC30AB22-38E9-4E46-B514-17B19A710244Q40443607-460611C6-65BB-427E-8677-4154402AF526Q40963346-29AE44D8-318E-40D5-BCCF-B8AAE414FEABQ42671934-74FCB0CB-B997-415B-9E1B-27D542685039Q42688884-4C8B3D96-F860-4E12-B8E6-AF287672D7FDQ43277955-2C1E2AB2-B77F-4826-BE63-923EB3972BE7Q43815698-48F53525-7525-41EA-AEF4-7028F495354AQ46116817-43AE85EE-C9AA-4B64-B899-50ADD9ECD730
P2860
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Efficacy and tolerability of s ...... r syndrome: a pooled analysis.
@en
Efficacy and tolerability of s ...... r syndrome: a pooled analysis.
@nl
type
label
Efficacy and tolerability of s ...... r syndrome: a pooled analysis.
@en
Efficacy and tolerability of s ...... r syndrome: a pooled analysis.
@nl
prefLabel
Efficacy and tolerability of s ...... r syndrome: a pooled analysis.
@en
Efficacy and tolerability of s ...... r syndrome: a pooled analysis.
@nl
P2093
P1476
Efficacy and tolerability of s ...... r syndrome: a pooled analysis.
@en
P2093
Adrian Wagg
Jean-Jacque Wyndaele
Paul Sieber
P356
10.1016/J.AMJOPHARM.2006.03.004
P577
2006-03-01T00:00:00Z